Skip to main content
Suman Paul, MD, Oncology, Baltimore, MD

SumanPaulMD

Oncology • Baltimore, MD

Physician

Join to view full profile

Dr. Paul is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Paul's full profile

Already have an account?

  • Office

    1800 Orleans Street
    Baltimore, MD 21287
    Phone+1 410-955-5000
    Fax+1 410-955-5001

Education & Training

  • Johns Hopkins University
    Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 2021
  • University of Toledo
    University of ToledoResidency, Internal Medicine, 2013 - 2016
  • University of Calcutta School of Medicine
    University of Calcutta School of MedicineClass of 2007

Certifications & Licensure

  • MD State Medical License
    MD State Medical License 2017 - 2025
  • OH State Medical License
    OH State Medical License 2013 - 2018
  • Internal Medicine
    American Board of Internal Medicine Internal Medicine
  • Medical Oncology
    American Board of Internal Medicine Medical Oncology

Publications & Presentations

PubMed

Lectures

  • Targeting MHC-linked wild type p53 with TCR mimic single chain diabody for cancer immunotherapy. 
    2019 ASCO Annual Meeting - 6/1/2019
  • Checkpoint Blockade Therapy May Sensitize Hodgkin Lymphoma to Subsequent Therapy 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Checkpoint Blockade Therapy May Sensitize Aggressive and Indolent Non-Hodgkin Lymphoma to Subsequent Therapy 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

  • Ludwig Johns Hopkins Researchers Devise New Strategy for Cancer Immunotherapy
    Ludwig Johns Hopkins Researchers Devise New Strategy for Cancer ImmunotherapyMarch 2nd, 2021
  • Breakthrough in Controlling T Cell Activation
    Breakthrough in Controlling T Cell ActivationMay 13th, 2014
  • Investigators Develop Novel Treatment for T-cell Leukemias and Lymphomas
    Investigators Develop Novel Treatment for T-cell Leukemias and LymphomasApril 3rd, 2024
  • Join now to see all

Grant Support

  • TCR Targeting Antibodies for the Treatment of T cell CancersJOHNS HOPKINS UNIVERSITY2022–2027
  • TCR Targeting Antibodies for the Treatment of T cell CancersJOHNS HOPKINS UNIVERSITY2022–2027

Dr. Suman Paul, Dr. Suman Paul, MD, Dr. S Paul